Clinical characteristics of clear cell ovarian cancer: A retrospective multicenter experience of 308 patients in South Korea

Hee Yeon Lee, Ji Hyung Hong, Jae Ho Byun, Hee Jun Kim, Sun Kyung Baek, Jin Young Kim, Ki Hyang Kim, Jina Yun, Jung A. Kim, Kwonoh Park, Hyo Jin Lee, Jung Lim Lee, Young Woong Won, Il Hwan Kim, Woo Kyun Bae, Kyong Hwa Park, Der Sheng Sun, Suee Lee, Min Young Lee, Guk Jin LeeSook Hee Hong, Yun Hwa Jung, Ho Jung An

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage. Materials and Methods Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected. Results Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease < 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence. Conclusion Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.

Original languageEnglish
Pages (from-to)277-283
Number of pages7
JournalCancer Research and Treatment
Volume52
Issue number1
DOIs
Publication statusPublished - 2020 Jan 1

Keywords

  • Adjuvant chemotherapy
  • Clear cell adenocarcinoma
  • Korea
  • Ovarian epithelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical characteristics of clear cell ovarian cancer: A retrospective multicenter experience of 308 patients in South Korea'. Together they form a unique fingerprint.

  • Cite this

    Lee, H. Y., Hong, J. H., Byun, J. H., Kim, H. J., Baek, S. K., Kim, J. Y., Kim, K. H., Yun, J., Kim, J. A., Park, K., Lee, H. J., Lee, J. L., Won, Y. W., Kim, I. H., Bae, W. K., Park, K. H., Sun, D. S., Lee, S., Lee, M. Y., ... An, H. J. (2020). Clinical characteristics of clear cell ovarian cancer: A retrospective multicenter experience of 308 patients in South Korea. Cancer Research and Treatment, 52(1), 277-283. https://doi.org/10.4143/crt.2019.292